| Dr Ruth Elizabeth Compton, DO | |
|
Usnh Guam, Bldg #50, Farenholt Ave, Tutuhan, GU 96910 | |
| (671) 344-9232 | |
| Not Available |
| Full Name | Dr Ruth Elizabeth Compton |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | Usnh Guam, Tutuhan, Guam |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831484047 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Shore Memorial Hospital | Onancock, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Riverside Physician Services Inc | 5092608448 | 743 |
News Archive
The S. Mark Taper Foundation awarded a grant of $30,000 to Valley Presbyterian Hospital (VPH) for its Stroke Center, a state-of-the-art facility using the latest in telemedicine and diagnostic tools to ensure the best possible outcomes for its patients, Gustavo Valdespino, President and CEO of VPH, announced today.
Investigators from the Boston University's Slone Epidemiology Center have reported findings that may shed light on why African American women have a disproportionately higher risk of developing more aggressive and difficult-to-treat breast cancers, specifically estrogen and progesterone receptor negative (ER-/PR-) cancers.
Each October, the color pink marks the arrival of National Breast Cancer Awareness Month. Media coverage, product promotions and even the football gridirons showcase the national effort to promote screenings and early detection of the cancer that 200,000 American women are diagnosed with each year.
People from lower socioeconomic backgrounds who suffer a heart attack come to the emergency department more often, are less likely to be treated aggressively and have higher mortality rates a year after the attack, says new University of Alberta research that has important implications for access to cardiac care.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
› Verified 4 days ago
| Entity Name | Riverside Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194929026 PECOS PAC ID: 5092608448 Enrollment ID: O20040207000400 |
News Archive
The S. Mark Taper Foundation awarded a grant of $30,000 to Valley Presbyterian Hospital (VPH) for its Stroke Center, a state-of-the-art facility using the latest in telemedicine and diagnostic tools to ensure the best possible outcomes for its patients, Gustavo Valdespino, President and CEO of VPH, announced today.
Investigators from the Boston University's Slone Epidemiology Center have reported findings that may shed light on why African American women have a disproportionately higher risk of developing more aggressive and difficult-to-treat breast cancers, specifically estrogen and progesterone receptor negative (ER-/PR-) cancers.
Each October, the color pink marks the arrival of National Breast Cancer Awareness Month. Media coverage, product promotions and even the football gridirons showcase the national effort to promote screenings and early detection of the cancer that 200,000 American women are diagnosed with each year.
People from lower socioeconomic backgrounds who suffer a heart attack come to the emergency department more often, are less likely to be treated aggressively and have higher mortality rates a year after the attack, says new University of Alberta research that has important implications for access to cardiac care.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ruth Elizabeth Compton, DO 1837 Steve Ln, Virginia Beach, VA 23454-3819 Ph: (631) 327-2772 | Dr Ruth Elizabeth Compton, DO Usnh Guam, Bldg #50, Farenholt Ave, Tutuhan, GU 96910 Ph: (671) 344-9232 |
News Archive
The S. Mark Taper Foundation awarded a grant of $30,000 to Valley Presbyterian Hospital (VPH) for its Stroke Center, a state-of-the-art facility using the latest in telemedicine and diagnostic tools to ensure the best possible outcomes for its patients, Gustavo Valdespino, President and CEO of VPH, announced today.
Investigators from the Boston University's Slone Epidemiology Center have reported findings that may shed light on why African American women have a disproportionately higher risk of developing more aggressive and difficult-to-treat breast cancers, specifically estrogen and progesterone receptor negative (ER-/PR-) cancers.
Each October, the color pink marks the arrival of National Breast Cancer Awareness Month. Media coverage, product promotions and even the football gridirons showcase the national effort to promote screenings and early detection of the cancer that 200,000 American women are diagnosed with each year.
People from lower socioeconomic backgrounds who suffer a heart attack come to the emergency department more often, are less likely to be treated aggressively and have higher mortality rates a year after the attack, says new University of Alberta research that has important implications for access to cardiac care.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
› Verified 4 days ago